中高危险度胃肠间质瘤患者术后治疗的预后分析

doi:10.3877/cma.j.issn.1674-3946.2021.04.030

目的

探索胃肠道间质瘤(GIST)使用甲磺酸伊马替尼(IM)靶向治疗的时机，为胃肠间质瘤患者提供个体化的治疗方案。

方法

回顾分析2011年至2017年收治的482例GIST患者的临床病理及随访资料，数据使用SPSS 22.0进行分析。对所有病例进行倾向评分匹配，使用χ²检验和多变量logistic回归进行分析，合并Kaplan-Meier方法用于术后生存分析。倾向性匹配卡钳值设为0.02, P<0.05差异有统计学意义。

结果

中高危险度患者术后IM辅助服药组比未服药组有更好的5年无复发生存时间(RFS) (71.8% vs. 53.8%, P＝0.026)和5年总体生存时间(OS) (76.0% vs. 54.7%, P＝0.045)，差异有统计学意义。随着治疗时间的增加，患者的3年OS和5年OS均增加，预后较好(OS，P＝0.006，RFS，P＝0.004)。

结论

GIST中高危险度患者术后靶向治疗能够改善预后，并且治疗时间的延长，能够进一步改善预后。

关键词: 胃肠间质瘤, 甲磺酸伊马替尼, 靶向治疗, 危险, 预后

Objective

In order to provide individualized therapeutic treatment for patients with gastrointestinal stromal tumor (GIST), we explored the timing of targeted therapy for gastrointestinal stromal tumor (GIST) with Imatinib mesylate (IM).

Methods

The clinicopathological and follow-up data of 482 GIST patients treated in our center from 2011 to 2017 were analyzed retrospectively, and all the data were analyzed by using SPSS 22.0 software. Propensity score matching was applied to all cases, then we analyzed the clinical data by using χ² test, multivariate logistic regression, and Kaplan-Meier method, which was used for analyzing postoperative survival. The value of propensity score matching calipers was set as 0.02, and a P value of < 0.05 was considered as statistically significant difference.

Results

The 5-year relapse-free survival (RFS) of 71.8% vs. 53.8% (P=0.026) and 5-year overall survival (OS) of 76.0% vs. 54.7% (P=0.045) of patients with medium to high risk of GIST were significantly better in patients who received IM treatment than the untreated patients. With increased therapuetic time with IM, 3/5-year OS of the patients were increased with improved prognosis (OS, P=0.006, RFS, P=0.004).

Conclusion

Targeted therapy after surgery could improve the prognosis of patients with medium to high-risk of GIST , and the increased IM treatment time could further improve the clinical outcome.

Key words: Gastrointestinal stromal tumor, Imatinib mesylate, Targeted therapy, Risk, Prognosis

表1 倾向匹配后148例GIST两组患者基本数据比较(例)

临床特征		未治疗组(n＝74)	治疗组(n＝74)	P值
年龄(岁)
	≤60	36	41	0.411
	>60	38	33	0.411
性别
	男性	37	33	0.510
	女性	37	41	0.510
肿瘤原发部位
	胃	47	51	0.487
	非胃	27	23	0.487
肿瘤直径(cm)
	≤5	14	14	0.473
	5～10	45	51
	>10	15	9
Ki-67指数(%)
	≤5	44	50	0.419
	6～10	21	14
	>10	9	10
危险度分级
	中	28	29	0.866
	高	46	45	0.866
核分裂数(个/50HPF)
	≤5	37	39	0.750
	5～10	17	8
	>10	20	27
基因分型
	C-kit 9	4	2	0.635
	C-kit 11	60	63
	PDGFRA 12	3	1
	PDGFRA 18	3	6
	野生型	4	2

表1 倾向匹配后148例GIST两组患者基本数据比较(例)

临床特征		未治疗组(n＝74)	治疗组(n＝74)	P值
年龄(岁)
	≤60	36	41	0.411
	>60	38	33	0.411
性别
	男性	37	33	0.510
	女性	37	41	0.510
肿瘤原发部位
	胃	47	51	0.487
	非胃	27	23	0.487
肿瘤直径(cm)
	≤5	14	14	0.473
	5～10	45	51
	>10	15	9
Ki-67指数(%)
	≤5	44	50	0.419
	6～10	21	14
	>10	9	10
危险度分级
	中	28	29	0.866
	高	46	45	0.866
核分裂数(个/50HPF)
	≤5	37	39	0.750
	5～10	17	8
	>10	20	27
基因分型
	C-kit 9	4	2	0.635
	C-kit 11	60	63
	PDGFRA 12	3	1
	PDGFRA 18	3	6
	野生型	4	2

图1 148例中高危险度GIST患者术后服药组与非服药组5年OS与RFS比较

图2 146例GIST术后不同伊马替尼治疗时间OS和RFS比较

表2 146例GIST术后不同伊马替尼治疗时间OS和RFS比较(%)

治疗时间	例	3年OS	5年OS	3年RFS	5年RFS
≤12月	39	78.60	60.20	73.40	57.40
12～36月	72	89.20	57.90	77.70	61.60
>36月	35	100	90.00	100	94.10
P值			0.006		0.004

表2 146例GIST术后不同伊马替尼治疗时间OS和RFS比较(%)

治疗时间	例	3年OS	5年OS	3年RFS	5年RFS
≤12月	39	78.60	60.20	73.40	57.40
12～36月	72	89.20	57.90	77.70	61.60
>36月	35	100	90.00	100	94.10
P值			0.006		0.004

[1]	von Mehren M, Joensuu H. Gastrointestinal Stromal Tumors[J]. J Clin Oncol, 2018, 36(2): 136-143.
[2]	Pang T, Zhao Y, Fan T, et al. Comparison of Safety and Outcomes between Endoscopic and Surgical Resections of Small (≤ 5 cm) Primary Gastric Gastrointestinal Stromal Tumors[J]. Journal of cancer, 2019, 10(17): 4132-4141.
[3]	王峰，宋鹏，汪灏，等.284例胃间质瘤临床特征及预后分析[J/CD]．中华普外科手术学杂志(电子版)，2017，11(2)：123-126.
[4]	Kim JH, Ryu M-H, Yoo C, et al. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience[J]. Cancer Medicine, 2019, 8(3): 1034-1043.
[5]	Badic B, Gancel CH, Thereaux J, et al. Surgical and oncological long term outcomes of gastrointestinal stromal tumors (GIST) resection- retrospective cohort study[J]. Int J Surg, 2018, 53: 257-261.
[6]	Xue A, Gao X, Fang Y, et al. Incorporation of NLR into NIH stratification system increases predictive accuracy for surgically resected gastrointestinal stromal tumors[J]. Acta Biochim Biophys Sin (Shanghai), 2017, 49(2): 179-185.
[7]	于恒，杜尚策，徐恩，等．影响胃肠道间质瘤预后因素的研究进展[J/CD]. 中华普外科手术学杂志(电子版)，2020，14(1)：97-100.
[8]	Lin J-X, Chen Q-F, Zheng C-H, et al. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up[J]. J Cancer Res Clin Oncol, 2017, 143(4): 727-734.
[9]	Zheng J, Li R, Qiu H, et al. Tumor necrosis and >20 mitoses per 50 high-power felds can distinguish 'very high-risk’ and 'highest-risk’ within 'high-risk’gastric gastrointestinal stromal tumor[J]. Future Oncol, 2018, 14(7): 621-629.
[10]	Xu C, Chen T, Hu Y, et al. Retrospective study of laparoscopic versus open gastric resection for gastric gastrointestinal stromal tumors based on the propensity score matching method[J]. Surg Endosc, 2017, 31(1): 374-381.
[11]	Liu X, Qiu H, Zhang P, et al. Prognostic factors of primary gastrointestinal stromal tumors: a cohort study based on high-volume centers[J]. Chin J Cancer Res, 2018, 30(1): 61-71.
[12]	Anderson W, O’Sullivan B, Hughes F, et al. Microscopic gastrointestinal stromal tumours: a clinical and molecular study of 13 cases[J]. Histopathology, 2017, 70(2): 211-216.
[13]	Yang Z, Feng X, Zhang P, et al. Clinicopathological features and prognosis of 276 cases of primary small (≤ 2 cm) gastric gastrointestinal stromal tumors: a multicenter data review[J]. Surg Endosc, 2019, 33(9): 2982-2990.
[14]	Tao K, Zeng X, Liu W, et al. Primary Gastrointestinal Stromal Tumor Mimicking as Gynecologic Mass: Characteristics, Management, and Prognosis[J]. J Surg Res, 2020, 246: 584-590.
[15]	Chen T, Ye L-Y, Feng X-Y, et al. Performance of risk stratification systems for gastrointestinal stromal tumors: A multicenter study[J]. World J Gastroenterol, 2019, 25(10): 1238-1247.
[16]	Joensuu H, Eriksson M, Hall KS, et al. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up[J]. JAMA Oncol, 2020, 6(8): 1241-1246.
[17]	Kurokawa Y, Yang H-K, Cho H, et al. Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach[J]. Br J Cancer, 2017, 117(1): 25-32.
[18]	Wang F, Tao T, Wang X, et al. Treatment options for giant gastrointestinal stromal tumors and related prognosis: a single-center retrospective study[J]. ANZ J Surg, 2020, 90(5): 762-766.
[19]	Lu J, Dai Y, Zheng H-L, et al. What is the appropriate duration of adjuvant imatinib mesylate treatment for primary gastrointestinal stromal tumors classified according to the strict definition of tumor rupture？[J]. Medicine (Baltimore), 2019, 98(3): e14177.
[20]	Zhao R, Wang Y, Huang Y, et al. Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: A Retrospective Cohort Study[J]. Sci Rep, 2017, 7 (1): 16834.

[1]	张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2]	许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3]	高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4]	李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5]	梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[6]	张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[7]	林凯, 潘勇, 赵高平, 杨春. 造口还纳术后切口疝的危险因素分析与预防策略[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 634-638.
[8]	杨闯, 马雪. 腹壁疝术后感染的危险因素分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 693-696.
[9]	陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[10]	陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[11]	刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[12]	陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[13]	曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[14]	王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15]	颜世锐, 熊辉. 感染性心内膜炎合并急性肾损伤患者的危险因素探索及死亡风险预测[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 618-624.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Prognosis analysis of patients with intermediate and high risk gastrointestinal stromal tumor after surgery

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Prognosis analysis of patients with intermediate and high risk gastrointestinal stromal tumor after surgery